Palvella Therapeutics (PVLA) News Today $54.15 +2.85 (+5.56%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Palvella Therapeutics to Present at Upcoming Healthcare Investor ConferencesAugust 28 at 7:30 AM | globenewswire.comPalvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High - What's Next?August 27, 2025 | marketbeat.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from AnalystsAugust 27, 2025 | americanbankingnews.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by BrokeragesAugust 24, 2025 | marketbeat.comInstitutional investors in Palvella Therapeutics, Inc. (NASDAQ:PVLA) have had a wonderful week after share price increased 13%August 23, 2025 | finance.yahoo.comPalvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% After Analyst UpgradeAugust 22, 2025 | americanbankingnews.comCanaccord Genuity Group Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $66.00August 21, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Reaches New 12-Month High - Here's What HappenedAugust 21, 2025 | marketbeat.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) StockAugust 21, 2025 | americanbankingnews.comPalvella Therapeutics price target raised to $66 from $52 at CanaccordAugust 19, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Announces Quarterly Earnings ResultsAugust 18, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)August 17, 2025 | theglobeandmail.comHC Wainwright Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock PriceAugust 17, 2025 | marketbeat.comChardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock PriceAugust 17, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Shares Up 3.6% - Time to Buy?August 16, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Reaches New 1-Year High - Still a Buy?August 15, 2025 | marketbeat.comPalvella Therapeutics price target raised to $75 from $38 at H.C. WainwrightAugust 15, 2025 | msn.comPalvella Therapeutics price target raised to $60 from $50 at ChardanAugust 15, 2025 | msn.comPalvella Therapeutics price target raised to $60 from $45 at StifelAugust 14, 2025 | msn.comPalvella Therapeutics reports Q2 EPS (86c), consensus (77c)August 14, 2025 | msn.comPalvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comPalvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025August 7, 2025 | globenewswire.comAnalysts Issue Forecasts for PVLA Q2 EarningsAugust 7, 2025 | marketbeat.comPalvella Therapeutics (PVLA) to Release Earnings on WednesdayAugust 7, 2025 | marketbeat.comPalvella Therapeutics initiated with an Outperform at Raymond JamesAugust 6, 2025 | msn.comRaymond James Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform RecommendationAugust 6, 2025 | msn.comLifeSci Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform RecommendationAugust 5, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated by Analysts at Lifesci CapitalAugust 5, 2025 | marketbeat.comPalvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 5, 2025 | globenewswire.comRoyce & Associates LP Invests $2 Million in Palvella Therapeutics, Inc. (NASDAQ:PVLA)July 29, 2025 | marketbeat.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from BrokeragesJuly 28, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist FinancialJuly 21, 2025 | marketbeat.comPVLA - Palvella Therapeutics Inc Sustainability - MorningstarJuly 9, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN RapamycinJuly 9, 2025 | msn.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJuly 3, 2025 | marketbeat.comPalvella Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.comStrid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)June 29, 2025 | marketbeat.comPVLA - Palvella Therapeutics Inc Key Metrics - MorningstarJune 27, 2025 | morningstar.comMPVLA - Palvella Therapeutics Inc Executives - MorningstarJune 26, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - MorningstarJune 24, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - NasdaqJune 24, 2025 | nasdaq.comPalvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN RapamycinJune 24, 2025 | msn.comPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%June 23, 2025 | globenewswire.comPalvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR InhibitorsJune 18, 2025 | globenewswire.comPalvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN RapamycinJune 13, 2025 | msn.comCantor Fitzgerald Comments on PVLA FY2026 EarningsJune 11, 2025 | marketbeat.comPalvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsJune 9, 2025 | globenewswire.comCitadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)June 9, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJune 8, 2025 | marketbeat.comToronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)June 2, 2025 | marketbeat.com Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Media Mentions By Week PVLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVLA News Sentiment▼0.931.09▲Average Medical News Sentiment PVLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVLA Articles This Week▼54▲PVLA Articles Average Week Get the Latest News and Ratings for PVLA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Palvella Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies OGN News Today DNLI News Today IBRX News Today CNTA News Today AGIO News Today IDYA News Today OCUL News Today HRMY News Today RXRX News Today IRON News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PVLA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
